how a protein capable of preventing programmed cell death can also promote it. Their study, led by Robert Horvitz, the David ...

The ongoing trial is assessing the drug's performance both as a standalone therapy and in combination with the programmed cell death protein 1 (PD-1) checkpoint inhibitor Keytruda. It is structured as ...

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

The mechanisms underlying skin renewal are still poorly understood. Interleukin-38 (IL-38), a protein involved in regulating ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug ...

A PD-1/VEGF bispecific antibody is a type of cancer drug designed to target both the programmed cell death protein 1, or PD-1, on immune cells and vascular endothelial growth factor, or VEGF, on tumor ...

Radiopharm Theranostics Ltd (ASX:RAD) has received approval from the Australian Ethics Committee to expand its trial to ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held ...

The Guildford, England-based liquid biopsy company is presenting the new test results at the American Association for Cancer Research's Special Conference, 'Liquid Biopsy: From Discovery to Clinical ...

While many people don't often eat this vegetable, maybe they should. Studies say compounds found in it could help protect you ...

Cell biology is the discipline of biological sciences that studies the structure, physiology, growth, reproduction and death of cells ... The RNA-binding protein FMRP regulates mitochondrial ...

The trial enrolled an estimated 378 patients who were randomized (2:1) to receive either subcutaneous pembrolizumab administered with chemotherapy or IV KEYTRUDA in combination with chemotherapy.